Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer

Gastric Cancer

Volumn 13, Issue 2, 2010, Pages 101-108

  Tamura, Shigeyuki ^a   Miki, Hirofumi ^a   Okada, Kaoru ^a   Takeno, Atsushi ^a   Uji, Kumiko ^a   Yoshida, Atsuko ^a   Suzuki, Rei ^a   Nakahira, Shin ^a   Egawa, Chiyomi ^a   Nakata, Ken ^a   Okamura, Shu ^a   Sugimoto, Keishi ^a   Takatsuka, Yuichi ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Advanced gastric cancer; Combination chemotherapy; Paclitaxel; Peritoneal dissemination; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DEXAMETHASONE; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LAPAROSCOPY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMACH CANCER; STOMACH SURGERY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; ADENOCARCINOMA; DRUG COMBINATION; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; PROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 78049259189     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-010-0547-2     Document Type: Article

References (41)

1. Kakeji Y, Maehara Y, Tomoda M, Kabashima A, Ohmori M, Oda S, et al. Long term survival of patients with stage IV gastric cancer. Cancer 1998;82:2307-2311
2. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-262
3. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, et al. Prophylaxis with carbon-absorbed mitomycin C against peritoneal recurrence of gastric cancer. Lancet 1992;339: 629-631
4. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study on novel oral fluoropyrimidine anticancer drug S-1 (IM Tegafur-0.4M Gimestat-1M Otastat Potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720
5. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197
6. Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 2002;9:811-5.
7. Kitamura Y, Hayashi K, Sasagawa T, Oguma H, Takasaki K. Pilot study of S-1 in patients with disseminated gastric cancer. Drugs Exp Clin Res 2003;29:125-130
8. Koizumi W, Tanabe S, Saigenji T, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212
9. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-3407
10. Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, et al. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006;95:1642-1647
11. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006;94: 1130-1135
12. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988;48:4093-4100
13. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 2006;12:1412-1415
14. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008;74:37-41.
15. Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, et al. Peritoneal wash cytology: Prognostic value of positive fi ndings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999;72:60-65
16. Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: An independent predictor of outcome. Ann Surg Oncol 1998;5:411-415
17. Tamura S, Miki H, Nakata K, Takiuchi D, Okada K, Nakahira S, et al. Intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer 2007;10:251-255
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. - 2nd English Edition -. Gastric Cancer 1998;1:10-24.
19. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. - 2nd English Edition - Response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 2001;4:1-8.
20. Sotiropoulos GC, Kaiser GM, Lang H, Treckmann J, Brokalaki EI, Pottgen C, et al. Staging laparoscopy in gastric cancer. Eur J Med Res 2005;10:88-91.
21. Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer 2007;10:29-34.
22. Oshima T, Yamada R, Hatori S, Kunisaki C, Imada T. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. Oncol Rep 2006;16:361-366
23. Hosokawa A, Sugiyama T, Ohtsu A, Doi T, Hattori S, Kojima T, et al. Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol 2007;42: 533-538
24. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-221
25. Dickinson R, Presgrave P, Levi J, Milliken S, Woods R. Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. Cancer Chemother Pharmacol 1989;24: 67-68
26. Pérez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, et al. Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. Am J Clin Oncol 1998;21:452-457 (Pubitemid 28480494)
27. Murakami M, Ota K, Miyazaki T, Niitsu Y, Wakui A, Yokoyama M, et al. Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment for patients with advanced gastric and colorectal cancer (in Japanese with English abstract). Gan To Kagaku Ryoho 1987;14:2482-2490
28. Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994;14: 1277-1280 (Pubitemid 2125921)
29. Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: A retrospective study. Gastric Cancer 2001;4:212-218
30. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: A report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004;34:316-322
31. Fushida S, Furui N, Kinami S, Ninomiya I, Fujimura T, Nishimura G, et al. Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination (in Japanese with English abstract). Gan To Kagaku Ryoho 2002;29:2164-2167
32. Yonemura Y, Endou Y, Bando E, Kuno K, Kawamura T, Kimura M, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 2004;210: 189-196
33. Markman M, Rowinsky E, Harkes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group Study. J Clin Oncol 1992;10:1485-1491
34. Tamura S, Miki H, Okada K, Miyake T, Yoshimura M, Suzuki R, et al. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. Int J Clin Oncol 2008;13:536-540
35. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction. Ann Oncol 2001; 12:1133-1137
36. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Paclitaxel Gastric Cancer Study Group in Japan, phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-95
37. Kodera Y, Ito S, Mochizuki Y, Fujikake S, Koshikawa K, Kanyama Y, et al. Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007;27:2667-2671
38. Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by 1-hour infusion for advanced gastric cancer. Surg Today 2008;38:1013-1020
39. Ueda Y, Yamagishi H, Ichikawa D, Mori J, Koizumi K, Kakihara N, et al. Phase I study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 2005;69:261-268
40. Li C, Yan M, Chen J, Xiang M, Zhu ZG, Yin HR, et al. Survival benefi t of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis. J Gastrointest Surg 2010; 14:282-288
41. Kodera Y, Ito S, Mochizuki Y, Kondo K. Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Sur Oncol 2009;35:1158-1163